Bromojimscaline

Bromojimscaline, or 7-bromojimscaline, is a serotonin 5-HT₂ receptor modulator of the phenethylamine and scaline families related to 2CB-Ind. It is the 7-bromo derivative of jimscaline, a cyclized phenethylamine analogue of mescaline with a 1-aminomethylindane structure. Bromojimscaline shows 1.6- and 4.2-fold higher affinities for the serotonin 5-HT_2A and 5-HT_2C receptors, respectively, than jimscaline. It also shows high affinity for the serotonin 5-HT_1A receptor. The drug was developed by David E. Nichols and colleagues at Purdue University and was subsequently reported by Daniel Trachsel in 2013, who obtained the information via personal communication with Nichols in 2010. It is not a controlled substance in Canada as of 2025.